Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-10T15:39:10.479Z Has data issue: false hasContentIssue false
  • English
  • Français

Plasma homovanillic acid, noradrenaline and psychotic symptoms in chronically medicated schizophrenic in patients

Published online by Cambridge University Press:  04 January 2019

Y. Kaneda  and
A. Fujii
Y. Kaneda*
Affiliation:
Department of Neuropsychiatry, The University of Tokushima School of Medicine, Tokushima, Japan Department of Neuropsychiatry, Fujii Hospital, Anan, Tokushima, Japan
A. Fujii
Affiliation:
Department of Neuropsychiatry, Fujii Hospital, Anan, Tokushima, Japan
*
Department of Neuropsychiatry, The University of Tokushima School of Medicine, Kuramoto-Cho, Tokushima, Tokushima 770-8503, Japan, Telephone number: +81 -88-633-7130, Facsimile number: +81-88-632-3214, E-mail: kaneday@clin.med.tokushima-u.ac.jp
Get access Rights & Permissions [Opens in a new window]

Summary

Objective:

The authors investigated plasma homovanillic acid (HVA) levels and noradrenaline (NA) in chronically medicated schizophrenic inpatients.

Methods:

The subjects were 55 inpatients who were diagnosed according to the DSM-IV criteria for schizophrenia. Nine normal subjects were compared to the patient group. Each patient gave informed consent for the research involved in this study. Psychiatric symptoms were assessed using the BPRS.

Results:

(1) The medicated schizophrenic inpatients had significantly greater plasma NA levels, and higher but nonsignificant plasma HVA levels than the normal subjects.

(2) In patients, there was a positive but nonsignificant correlation between the plasma NA levels and positive symptomatology. In contrast, plasma HVA levels were not correlated with either positive or negative symptomatology.

Conclusion:

On the basis of these results, we hypothesize that, mainly because of their catecholaminergic dysfunction, there is an increase in plasma NA and a tendency for increased plasma HVA in patients with chronic schizophrenia, regardless of long-term neuroleptic medication.

Keywords

clinical psychopathologyneurolepticsnoradrenalineplasma homovanillic acidschizophrenia
Type
Articles
Information
Acta Neuropsychiatrica , Volume 13 , Issue 2 , June 2001 , pp. 49 - 52
Copyright
Copyright © Cambridge University Press 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Bacopoulos, NG, Hattox, SE, Roth, RH. 3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur J Pharmacol 1979;56:225–236.Google Scholar
2. Kendler, KS, Heninger, GR, Roth, RH. Influence of dopamine agonists on plasma and brain levels of homovanillic acid. Life Sci 1982;30:2063–2069.Google Scholar
3. Lieberman, JA, Koreen, AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 1993;19:371–429.Google Scholar
4. Randrup, A, Munkvad, I. Evidence indicating an association between schizophrenia and dopaminergic hyperactivity in the brain. Orthomol Psychiatry 1972;1:2–7.Google Scholar
5. Maas, JW, Contreras, SA, Miller, AL, Berman, N, Bowden, CL, Javors, MA, Seleshi, E, Weintraub, S. Studies of catecholamine metabolism in schizophrenia/psychosis-I. Neuropsychopharmacol 1993;8:97–109.Google Scholar
6. Pickar, D, Labarca, R, Linnoila, M, Roy, A, Hommer, D, Everett, D, Paul, SM. Neuroleptic-induced decrease in plasma homovanillic acid and antipsycholic activity in schizophrenic patients. Science 1984;225:954–957.Google Scholar
7. Beuger, M, Van Kammen, DP, Kelley, ME, Yao, J. Dopamine Turnover in Schizophrenia Before and after Haloperidol Withdrawal: CSF, Plasma, and Urine Studies. Neuropsychopharmacol 1996;15:75–86.Google Scholar
8. Northoff, G, Demisch, L, Wenke, J, Pflug, B. Plasma homovanillic acid concentrations in catatonia. Biol Psychiatry 1996;39:436–443.Google Scholar
9. Dajas, F, Barbeito, L, Martinez-Pesquera, G, Lista, A, Puppo, D. Puppo- Touriz H. Plasma noradrenaline and clinical psychopathology in schizophrenia. A correlation analysis. Neuropsychobiol 1983;10:70–4.Google Scholar
10. Kemali, D, Del Vecchio, M, Maj, M. Increased noradrenaline levels in CSF and plasma of schizophrenic patients. Biol Psychiatry 1982;17:711–777.Google Scholar
11. Wei, J, Ramchand, CN, Hemmings, GP. Studies on concentrations of NA and HVA and activity of DBH in the serum from schizophrenic patients, first-degree relatives and normal subjects. Schizophr Res 1992;8:103–110.Google Scholar
12. Garelis, E, Gillin, JC, Wyatt, RJ, Neff, N. Elevated blood serotonin concentrations in unmediated chronic schizophrenic patients: a preliminary study. Am J Psychiatry 1975;132:184–186.Google Scholar
13. Kaneda, Y, Fujii, A, Nagamine, I. Platelet serotonin concentrations in medicated schizophrenic patients (in press). Prog Neuropsychopharmacol Biol Psychiatry.Google Scholar
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (DSM-IV). Washington, D.C., American Psychiatric Association, 1994.Google Scholar
15. Inagaki, A, Inada, T, Fujii, Y, Yagi, K. Dose equivalence of psychotropic drugs. Part 4. Dose equivalence of orally administered neuroleptics (4) (in Japanese). Rinsyo Seisin Yakuri. Japanese Journal of Clinical Psychopharmacology 1998;1:443–448.Google Scholar
16. Inagaki, A, Inada, T, Fujii, Y, Yagi, K. Dose equivalence of psychotropic drugs. Part 6. Dose equivalence of depot administered neuroleptics (2) (in Japanese). Rinsyo Seisin Yakuri. Japanese Journal of Clinical Psychopharmacology 1998;1:557–561.Google Scholar
17. Overall, JE, Gorham, DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799–812.Google Scholar
18. Crow, TJ. The two-syndrome concept: origins and current status. Schizophr Bull 1985;11:471–486.Google Scholar
19. Guy, W. ECDU assessment manual, Rockville, US Department of Health Education and Welfare, 1976.Google Scholar
20. Kitamura, T, Shima, S, Kato, M, Iwashita, S, Kanba, S, Shiratsuchi, T, Fujihara, S, Ikuta, Y, Kato, M, Kanba, K, Iino, T, Ikuta, N, Miyaoka, H, Takei, S, Hiyama, M, Koshikawa, H, Tsugeno, M, Chiba, C. Positive and negative symptoms of chronic schizophrenia (in Japanese). Seishin Igaku 1989;31:131–136.Google Scholar
21. Nicholson, IR, Chapman, JE, Neufeld, RW. Variability in BPRS definitions of positive and negative symptoms. Schizophr Res 1995;17:177–185.Google Scholar
22. Gironi, A, Seghieri, G, Niccolai, M, Mammini, P. Simultaneous liquid-chromatographic determination of urinary vanillylmandelic acid, homovanillic acid, and 5-hydroxyindoleacetic acid. Clin Chem 1988;34:2504–2506.Google Scholar
23. Tsuji, U, Nakanishi, T, Nakai, K, Shiomi, J, Funahashi, S. Measurement of catecholamine fractionation in blood and urine using Automatic Catecholamine Analyzer (HLC-8030) (in Japanese). Rinsho Kensa Kiki Shiyaku 1988;11:635–641.Google Scholar
24. Chang, WH, Chen, TY, Lee, CF, Hung, JC, Hu, WH, Yeh, EK. Plasma homovanillic acid levels and subtyping of schizophrenia. Psychiatr Res 1988;23:239–244.Google Scholar
25. Koreen, AR, Lieberman, J, Alvir, J, Mayerhoff, D, Loebel, A, Chakos, M, Amin, F, Cooper, T. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. Arch Gen Psychiatry 1994;51:132–138.Google Scholar
26. Mazure, CM, Nelson, JC, Jatlow, PI, Bowers, MB. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry 1991;30:475–482.Google Scholar
27. Davidson, M, Kahn, RS, Knott, P, Kaminsky, R, Cooper, M, DuMont, K, Apter, S, Davis, KL. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry 1991;48:910–913.Google Scholar
28. Davidson, M, Kahn, RS, Powchik, P, Warne, P, Losonczy, MF, Kaminsky, R, Apter, S, Jaff, S, Davis, KL. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry 1991;48:73–76.Google Scholar
29. Davis, KL, Davidson, M, Mohs, RC, Kendler, KS, Davis, BM, Johns, CA, DeNigris, Y, Horvath, TB. Plasma homovanillic acid concentration and the severity of schizophrenic illness. Science 1985;227:1601–1602.Google Scholar
30. Newcomer, JW, Riney, SJ, Vinogradov, S, Csernansky, JG. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. Psychiatr Res 1992;41:191–202.Google Scholar
31. Davidson, M, Davis, KL. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry 1988;45:561–563.Google Scholar
32. Kahn, RS, Davis, KL. New Developments in dopamine and schizophrenia. In: Watson, SJ (ed). Psychopharmacology on CD-ROM, Philadelphia, PA, Lippincolt Williams & Wilkins Publishers, 1998.Google Scholar
33. Kopin, IJ, Bankiewicz, KS, Harvey-White, J. Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: validation in monkeys treated with MPTP. Neuropsychopharmacol 1988;1:119–125.Google Scholar